Johnson & Johnson (J&J) has announced that it has successfully completed its acquisition of Ambrx Biopharma in an all-cash merger transaction with a total equity value of approximately $2bn. The acquisition is intended to help J&J design, develop and commercialise targeted oncology therapeutics, utilising Ambrx’s proprietary antibody drug conjugate (ADC) technology, which ‘incorporates the advantages […]
The post Johnson & Johnson acquires Ambrx Biopharma for approximately $2bn appeared first on Pharmafile.
